Drug Channels

NOVEMBER 28, 2023

In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference!

Pharmacy 74

Pharmacy Drugs Cardiology Marketing 74

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. Gackowska has led international teams dedicated to clinical trials management, product launch, market access, marketing, and sales.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

BioTech 365

SEPTEMBER 2, 2020

NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, … Continue reading → SOUTH JORDAN, Utah, Sept.

Radiology 40

Radiology Cardiology Manufacturing Marketing 40

Velocity Clinical Research

NOVEMBER 21, 2023

“I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. The site has 2 full-time investigators and cooperates closely with specialists for internal medicine, orthopedics, neurology, and cardiology.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

Drug Discovery World

JUNE 27, 2023

Janssen has submitted a marketing authorisation application to the European Medicines Agency (EMA) seeking approval of single tablet combination therapy (STCT) of macitentan and tadalafil for pulmonary arterial hypertension (PAH).

Cardiology 52

Cardiology Drugs Medicine Marketing 52

XTalks

APRIL 7, 2022

The LEADLESS II–Phase 2 study was published in the Journal of the American College of Cardiology: Clinical Electrophysiology. According to a report by Persistence Market Research, the market for leadless pacemakers was estimated to be $29.4 The study showed that the implant success was 98 percent and 83.2

FDA Approval 105

FDA Approval Clinical Trials Clinical Trials Cardiology 105

Velocity Clinical Research

MARCH 7, 2024

Currently, he serves on multiple journal editorial boards focusing on Cardiology and Lipidology and has been published in dozens of peer-reviewed publications, books, and abstracts.

Doctors 52

Doctors Doctor Clinical Research Clinical Trials 52

pharmaphorum

AUGUST 18, 2021

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga. Sales have rocketed ever since, climbing 30% to almost $2 billion last year, and 60% to $1.36 billion in the first half of 2021.

Cardiology 52

Cardiology Sales Marketing FDA Approval 52

pharmaphorum

FEBRUARY 17, 2022

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug, acquired as part of its $13.1 billion takeover of MyoKardia in 2020.

Cardiology 59

Cardiology Trials Marketing Drugs 59

pharmaphorum

JUNE 17, 2022

The licensing deal took place as AZ was trimming down its pipeline to focus its R&D activities on the core areas of cardiology, diabetes and neurology, and recovering from a series of patent expiries that hit its revenues. Since then it has bounced back dramatically, thanks to fast-growing drugs for cancer and heart disease.

Licensing 81

Licensing Licensing Cardiology Antibody 81

pharmaphorum

JULY 14, 2022

The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.

Drugs 97

Drugs Sales Pharma Companies Cardiology 97

pharmaphorum

JUNE 25, 2021

But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In But one of the biggest issues in changing people’s expectations and improving outcomes is “apathy”, he says.

Cardiology 100

Cardiology Drugs Development Clinical Trials 100

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) in January 2021 and was recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) in the EU in May 2021. Additionally, it has been submitted for marketing authorization in China, as well as multiple other countries worldwide. Kenilworth, NJ, USA).

Cardiology 52

Cardiology Production Development Medicine 52

WCG Clinical

MAY 22, 2023

3 One finding was particularly interesting: Respondents who saw the pursuit of diversity as a scientific or ethical imperative felt more strongly about its importance than did those who considered diversity to be important primarily for regulatory or marketing reasons. Current Problems in Cardiology. 2019;44(5):148-172. March 29, 2023.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Cardiology 52

pharmaphorum

JULY 7, 2021

The top-line data sets up a possible market clash with Novartis, which secured the first FDA approval for a drug treatment for HFpEF in February, although the label for its Entresto (sacubitril/valsartan) drug says that its benefits are more evident in patients with reduced ejection fraction.

Sales 52

Sales Cardiology FDA Approval Trials 52

ACRP blog

JANUARY 24, 2023

Central to the success of our approach were strategic communications and marketing plans, which enabled us to deliver on ambitious development goals in clinical research,” explains Danielle Eaton, MBA, Director of Clinical Research at Renown Health and University of Nevada, Reno, School of Medicine.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

DECEMBER 16, 2021

Wellthy enables biopharma & medtech to deploy and scale these solutions, accelerating time to market, while minimising risk and cost. Dr Tunnah holds a BA in Biochemistry and DPhil in Biological Sciences from Oxford University. The post Digital Innovators: Wellthy Therapeutics’ Abhishek Shah appeared first on.

Pharma Companies 52

Pharma Companies Cardiology Life Science Marketing 52

pharmaphorum

MAY 18, 2021

billion acquisition of Corvidia Therapeutics in June last year, The deal saw the firm begin to explore new markets after making its name in diabetes, a market which is being squeezed by pricing pressures. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

The launch enables physicians to reach previously inaccessible areas of the heart for procedure mapping, by making available the smallest diagnostic catheter in the Canadian electrophysiology market. The EPstar catheters are widely used in the Japanese electrophysiology market and were launched in the United States market in 2019.

Cardiology 52

Cardiology Manufacturing Marketing Production 52

pharmaphorum

FEBRUARY 25, 2022

. “While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure,” says Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research.

FDA Approval 101

FDA Approval HR Cardiology Drugs 101

The Pharma Data

NOVEMBER 2, 2020

market opens on Tuesday, November 17, 2020. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. The Company will host a conference call that day at 8:00 a.m.

Cardiology 52

Cardiology Marketing Development 52

The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

OCTOBER 14, 2020

“The global heart failure market represents a tremendous opportunity for Sequana Medical and we look forward to providing an update on the interim results from our RED DESERT study later this year.”. market for the alfa pump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

pharmaphorum

JUNE 22, 2021

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance. . The FDA removed the boxed warning for those risks last year but the product hasn’t recovered commercially.

Sales 98

Sales Marketing FDA Approval Regulation 98

XTalks

JULY 19, 2021

“We successfully brought a medical-grade test, analogs of which are billed by the big players anywhere from $1,500 – $10,000, to a price point more accessible to the consumer market at $249.”. Bisignano added that, “It is time we finally made a medical-grade genetic test available as a proactive, preventative tool.

Genetics 98

Genetics Genome Genomics Gene 98

Medical Xpress

DECEMBER 21, 2022

Identifying early risks and treatments among children and mothers, continued health disparities and finding new ways to use medications already on the market are among some of the significant scientific research developments in the fight against heart disease and stroke that emerged in 2022.

Research 94

Research Marketing Development Cardiology 94

The Pharma Data

NOVEMBER 11, 2021

MSD has the marketable rights to vericiguat in theU.S. and Bayer has the exclusive marketable rights in the rest of world. The cardiology ballot at Bayer formerly includes a number of products and several other composites are in colorful stages of preclinical and clinical development.

Cardiology 40

Cardiology Branding Development Production 40

The Pharma Data

MARCH 13, 2022

In connection with the acquisition, Arena’s shares of common stock will be delisted from the Nasdaq Global Select Market on or about March 11, 2022. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.

Dermatology 52

Dermatology Cardiology Development Medicine 52

pharmaphorum

AUGUST 13, 2020

The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing application by 11 February after a truncated six-month review.

Drugs 52

Drugs Antibody Sales Cardiology 52

XTalks

FEBRUARY 9, 2024

As we delve into the top 15 cardiovascular disease drugs in 2023, guided by comprehensive 2022 sales data, we gain valuable insights into the market trends, drug efficacy and the evolving needs of patients worldwide. Eliquis’ growing success in recent years owes largely to gains in the non-valvular atrial fibrillation market.

Sales 59

Sales FDA Approval Drugs Marketing 59

XTalks

JUNE 26, 2023

According to Surmodics, SurVeil DCB is approved to be marketed and sold in the US for percutaneous transluminal angioplasty of de novo or restenotic lesions in femoral and popliteal arteries having reference vessel diameters of 4 mm to 7 mm.

FDA Approval 96

FDA Approval Drugs Sales In-Vitro 96

Delveinsight

AUGUST 3, 2021

DelveInsight’s analysis in the report titled, DelveInsight’s Chronic Pain associated with Painful Diabetic Neuropathy – Epidemiology Forecast – 2030 Market Insights, Competitive Landscape and, Market Forecast – 2026 , the market size of the Senza Omnia system is estimated to increase to around USD 3,500 million by 2026.

FDA Approval 98

FDA Approval Marketing Cardiology Production 98

Delveinsight

DECEMBER 29, 2020

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.

Trials 52

Trials Drugs Hormones Radiology 52

The Pharma Data

JULY 12, 2021

Finerenone has also been submitted for marketing authorization in the European Union (EU) and in China, as well as multiple other countries worldwide and these applications are currently under review. FDA has approved finerenone for marketing authorization in the U.S. Based on the positive data from FIDELIO-DKD, the U.S.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

Delveinsight

AUGUST 4, 2020

Billion deal in a thirst to grow in the cancer market. Siemens Healthineers, formed as a result of spin-off in 2018, plans to increase its presence in oncology, neurology as well as cardiology domain. German health group Siemens Healthineers disclosed its plan to acquire Varian Medical Systems in a USD 16.4

Cardiology 55

Cardiology Antibody FDA Approval Trials 55

The Pharma Data

JANUARY 26, 2021

Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. The Company’s key product, WatchPAT, is commercially available within major markets including the US, Japan, and Europe.

Cardiology 40

Cardiology Doctors Doctor Marketing 40

The Pharma Data

OCTOBER 15, 2020

15, 2020 — CBD has been widely marketed as a cure-all for whatever ails you, and a new study finds many Americans are buying the sales pitch. The wave of marijuana legalization in the United States has led to a massive surge of CBD products being marketed across the nation, researchers said. THURSDAY, Oct.

Production 52

Production Medicine Doctors Doctor 52